A new study suggests that the cholesterol-regulating protein PCSK9 may serve as a sensitive early biomarker for autoimmune ...

Research suggests certain blood types may be linked to a higher risk of developing serious or fatal liver disease. Scientists ...

Findings indicate blood group A elevates the risk of primary biliary cholangitis, suggesting ABO group analysis could aid in ...

Elafibranor (Iqirvo) was well tolerated and led to sustained improvements in liver enzyme levels and itch severity through 28 weeks in patients with primary sclerosing cholangitis (PSC), according to ...

| DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- According to DataM Intelligence, the Primary Biliary Cholangitis (PBC) Treatment Market reached USD 1.33 billion in 2024 and ...

In this video, Julius Wilder, MD, PhD, discusses early results from the ongoing phase 2 ELMWOOD open-label extension trial of elafibranor in patients with primary sclerosing cholangitis.“Some of the ...

LISCure Biosciences ('LISCure'), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 clinical trial of LB-P8, a novel therapeutic candidate for ...

The soccer host began posting updates about his health after viewers reached out saying they were worried about his eyes, which appeared yellow.

Data expected H2 2026Rare liver disease with no approved treatment, typically concurrent with Inflammatory Bowel Disease (IBD)Second YAQ001 ...

In this video, Marlyn Mayo, MD, of the University of Texas Southwestern Medical Center, discusses data that shed light on the unmet needs in the management of pruritus in patients with primary ...

Learn how blood types A, B, and O may influence susceptibility and risk assessment for autoimmune liver disease.

Please contact your Oppenheimer representative to register for the Movers in Rare Disease Summit and to schedule a 1x1 meeting with Dr. Mor and Chemomab management.